New cholesterol drug RN5681 enters first human safety trial

NCT ID NCT07347678

Recruiting now Disease control Sponsor: Ikaria Bioscience Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 21, 2026 · Updated 18 times

Summary

This early-stage study tests a single dose of the experimental drug RN5681 in 60 healthy adults with high cholesterol. The main goal is to check safety and how the body processes the drug. Researchers will also look at changes in cholesterol levels over time. Participants receive either the drug or a placebo and are monitored for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH CHOLESTEROL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nucleus Network Pty Ltd.
RECRUITING

Melbourne, Victoria, 3004, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Q-Pharm Pty Ltd.
RECRUITING

Brisbane, Queensland, 4006, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HIGH CHOLESTEROL